ClinicalTrials.gg
Not yet recruitingNCT07585786LSD-RFPHUpdated May 18, 2026

Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

An observational study in Cirrhosis, Liver, Splenectomy; Status and Renal Function Abnormal, sponsored by Northern Jiangsu People's Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Northern Jiangsu People's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital — 8 open to participants now, 8 under way, none of them phase 3. Liver Cirrhosis · Northern Jiangsu People's Hospital.

Started
2026
with 3 others
Observational
6 of 11
4 open now
Registered
7th of 11
by date

Among the 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital, this one is one of 4 that started in 2026, is one of 6 observational ones, and was the 7th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

8 of the 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital, or all of them as a file.
02

Study summary

Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether LSD can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .

Read the detailed description

Liver cirrhosis is associated with systemic hemodynamic disturbances, reduced effective circulating volume, and renal hypoperfusion, creating a high risk of renal dysfunction and hepatorenal syndrome (HRS)-a life-threatening condition reflecting the critical hepatorenal interaction. Patients with cirrhosis, Portal Hypertension Bleeding frequently have subclinical or overt renal impairment preoperatively. LSD is a standard intervention for Cirrhosis Patients With Portal Hypertension Bleeding, but perioperative stress, hemodynamic fluctuations, and surgical trauma may further compromise renal function, and LSD may improve kidney function in the long term. Current evidence lacks prospective, 2-year data on renal function changes after LS in this high-risk population, especially regarding the hepatorenal axis and long-term renal outcomes. This study aims to fill this gap to guide perioperative renal protection strategies.

03

Conditions studied

  • Cirrhosis, Liver
  • Splenectomy; Status
  • Renal Function Abnormal
  • Portal Hypertension

Keywords

  • Cirrhosis
  • Splenectomy
  • Laparoscopy
  • azygoportal disconnection
  • Renal function
  • Portal hypertension bleeding
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Prospective, single-center, observational cohort study with a total duration of 24 months (2 years). Patients with cirrhosis, Splenomegaly and hypersplenism, Portal Hypertension Bleeding scheduled for Laparoscopic Splenectomy and Azygoportal Disconnection will be enrolled and followed for 2 years to assess renal function dynamics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
  2. Splenomegaly and hypersplenism
  3. History of portal hypertension bleeding (esophageal and gastric variceal bleeding )
  4. Age 18-80 years, male or female
  5. Class A or B liver function
  6. No history of primary renal disease or acute kidney injury (AKI)
  7. Signed written
  8. Ability to complete 24-month follow-up

Exclusion criteria

Exclusion Criteria:

  1. Class C liver cirrhosis
  2. Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)
  3. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection
  4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders
  5. Hepatic encephalopathy or ascites within 1 month before surgery
  6. Pregnancy or lactation
  7. Poor compliance, inability to complete follow-up
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Serum creatinine (Scr) level

    Change in serum creatinine (Scr) level

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

  2. Glomerular filtration rate (eGFR)

    Change in estimated glomerular filtration rate (eGFR). For females: If serum creatinine (Scr) ≤ 0.7 mg/dL: eGFR = 142 × (Scr/0.7)\^(-0.241) × (0.9938)\^Age; If Scr \> 0.7 mg/dL: eGFR = 142 × (Scr/0.7)\^(-1.200) × (0.9938)\^Age. For males: If Scr ≤ 0.9 mg/dL: eGFR = 142 × (Scr/0.9)\^(-0.302) × (0.9938)\^Age; If Scr \> 0.9 mg/dL: eGFR = 142 × (Scr/0.9)\^(-1.200) × (0.9938)\^Age. Note: Results are in mL/min/1.73 m². Age is in years.

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

  3. BUN and UA level

    Changes in BUN and UA level

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

  4. Urine albumin-to-creatinine ratio (UACR)

    Changes in urine albumin-to-creatinine ratio \[UACR (mg/g) = Urine albumin concentration (mg/L) ÷ Urine creatinine concentration (g/L)\]

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Secondary outcomes

  1. Intraoperative variables

    operation time, intraoperative blood loss, fluid infusion

    Time frame: During the procedure of operation

  2. Postoperative complications

    postoperative complications (bleeding, infection, hepatic encephalopathy, ascites)

    Time frame: at preoperative baseline, postoperative day 1, day 3, day 7, month 1, month 3, month 6, month 12, month 18, month 24

  3. Child-Pugh grade

    Changes in Child-Pugh grade The Child-Pugh score is calculated based on five parameters, each assigned 1, 2, or 3 points. 1. Total bilirubin * Less than 2 mg/dL: 1 point * 2-3 mg/dL: 2 points * Greater than 3 mg/dL: 3 points 2. Serum albumin * Greater than 3.5 g/dL: 1 point * 2.8-3.5 g/dL: 2 points * Less than 2.8 g/dL: 3 points 3. Prothrombin time prolongation or INR * Prolongation less than 4 seconds (INR \< 1.7): 1 point * Prolongation 4-6 seconds (INR 1.7-2.3): 2 points * Prolongation greater than 6 seconds (INR \> 2.3): 3 points 4. Ascites * None: 1 point * Mild or controlled with diuretics: 2 points * Moderate to severe or refractory: 3 points 5. Hepatic encephalopathy * None: 1 point * Grade I-II: 2 points * Grade III-IV: 3 points Total score and corresponding grade * 5-6 points: Child-Pugh class A * 7-9 points: Child-Pugh class B * 10-15 points: Child-Pugh class C

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

  4. Albumin and bilirubin level

    Changes in albumin and bilirubin level

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Feb 2029, 33 months later.

Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 33 months is below that.

Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 14, 2026
StartEst.
May 1, 2026
Primary completionEst.
Feb 28, 2029
CompletionEst.
Feb 28, 2029
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07585786
Lead sponsor
Northern Jiangsu People's Hospital
Responsible party
Guo-Qing Jiang (Clinical Professor, Northern Jiangsu People's Hospital) — Principal investigator
First posted
May 14, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Feb 28, 2029 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
May 18, 2026

Study contacts

Guo-Qing Jiang, MD
Contact
jgqing2003@hotmail.com
+8651487373272
Dou-Sheng Bai, MD
Contact
bdsno1@hotmail.com
+8651487373372
Guo-Qing Jiang, MD
study chair · Clinical Medical College of Yangzhou University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion